Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
Apolipoprotein E (apoE) and its receptor, very low density lipoprotein receptor (VLDLR), are involved in fat accumulation in adipocytes. Here, we investigated the effect of a peroxisome proliferator-activated receptor (PPAR) gamma agonist, rosiglitazone, on regulation of VLDLR expression both in white adipose tissue (WAT) of obese mice and in cultured adipocytes. Furthermore, to determine whether rosiglitazone directly regulates transcription of the VLDLR gene, we carried out luciferase assay with a reporter gene containing mouse VLDLR promoter region, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay. Four-day treatment with rosiglitazone increased the expression of VLDLR in WAT of ob/ob mice. Moreover, rosiglitazone increased the expression of VLDLR in cultured adipocytes. The PPAR-responsive element (PPRE)-directed mutagenesis analyses revealed that the PPRE motif in the VLDLR promoter region plays a significant role in transcriptional activation of the VLDLR gene in adipocytes. In addition, electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrated that endogenous PPARgamma directly binds to this functional PPRE motif in the VLDLR promoter region. We also investigated the effects of rosiglitazone on insulin sensitivity and lipid accumulation in both ob/ob mice and apoE-deficient ob/ob mice. Rosiglitazone ameliorated insulin sensitivity in both ob/ob mice and apoE-deficient ob/ob mice, possibly through decreasing the expression of monocyte chemoattractant protein-1 (MCP-1), increasing the expression of superoxide dismutase 1 (SOD1) in WAT, and increasing plasma adiponectin concentration. In ob/ob mice, body weight and WAT weight were significantly higher in the mice treated with rosiglitazone than those treated with vehicle. However, in apoE-deficient ob/ob mice, no significant difference in body weight or WAT weight was observed between the vehicle-treated group and the rosiglitazone-treated group. Moreover, rosiglitazone did not increase body weight and WAT weight in VLDLR-deficient mice. These findings indicate that rosiglitazone directly increases VLDLR expression, thereby enhancing apoE-VLDLR-dependent lipid accumulation in adipocytes.
Takazawa
Takeshi
T
Department of Metabolic Diseases, Graduate School of Medicine, 22nd Century Medical and Research Center, University of Tokyo, Tokyo, Japan.
Yamauchi
Toshimasa
T
Tsuchida
Atsushi
A
Takata
Makoto
M
Hada
Yusuke
Y
Iwabu
Masato
M
Okada-Iwabu
Miki
M
Ueki
Kohjiro
K
Kadowaki
Takashi
T
D017667:Adipocytes / Q000378:metabolism*; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000502:physiology; D001665:Binding Sites; D050356:Lipid Metabolism; D008297:Male; D051379:Mice; D008820:Mice, Obese; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014158:Transcription, Genetic; D015854:Up-Regulation / Q000187:drug effects* / Q000235:genetics
D001057:Apolipoproteins E; D047495:PPAR gamma; D011973:Receptors, LDL; D045162:Thiazolidinediones; C036053:VLDL receptor; D000077154:Rosiglitazone
Cell. 1996 Nov 1;87(3):377-89
8898192
J Biol Chem. 1995 Jun 2;270(22):12953-6
7768881
Diabetologia. 1999 Sep;42(9):1033-49
10447513
Endocrinology. 1994 Aug;135(2):798-800
8033830
J Biol Chem. 1991 Jul 25;266(21):13936-40
1713211
J Biol Chem. 1994 Jan 21;269(3):2173-82
8294473
Cell. 1994 Dec 30;79(7):1147-56
8001151
Endocrinology. 2001 Mar;142(3):1269-77
11181544
J Clin Invest. 2001 Oct;108(7):1001-13
11581301
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252-6
1384047
J Clin Invest. 2000 Nov;106(10):1221-8
11086023
J Biol Chem. 2002 May 3;277(18):15703-11
11867619
J Clin Invest. 2003 Dec;112(12):1796-808
14679176
J Clin Invest. 2004 Dec;114(12):1752-61
15599400
Nature. 2000 May 25;405(6785):421-4
10839530
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1488-93
11557677
Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1423-9
12842848
Biochem Biophys Res Commun. 2001 Aug 31;286(4):735-41
11520059
Nature. 2003 Jun 12;423(6941):762-9
12802337
Diabetes. 2001 Aug;50(8):1863-71
11473050
Cell. 1999 Oct 29;99(3):239-42
10555139
J Clin Invest. 1989 Jan;83(1):137-42
2521341
J Biol Chem. 1995 Jun 30;270(26):15747-54
7797576
J Clin Invest. 2003 Dec;112(12):1821-30
14679177
J Lipid Res. 2004 Aug;45(8):1475-81
15145981
Diabetes. 2005 Dec;54(12):3358-70
16306350
J Biol Chem. 2003 Jan 24;278(4):2461-8
12431986
J Clin Invest. 1998 Mar 15;101(6):1354-61
9502777
Diabetes. 2007 Jan;56(1):24-33
17192461
J Biol Chem. 2002 Jul 19;277(29):25863-6
12032136
J Biol Chem. 1991 Jun 5;266(16):10583-8
1709937
Biochem Biophys Res Commun. 2008 Apr 11;368(3):716-22
18262491
J Biol Chem. 2002 Mar 22;277(12):10037-43
11790777
J Biol Chem. 2001 Nov 2;276(44):41245-54
11533050
Endocrinology. 1994 Jul;135(1):387-94
8013374
Nat Med. 2001 Aug;7(8):941-6
11479627
Annu Rev Biochem. 1985;54:699-727
3896129